1. Novel Clinical, Immunological, and Metabolic Features Associated with Persistent Post-Acute COVID-19 Syndrome
- Author
-
Karina Santana-de Anda, Jiram Torres-Ruiz, Nancy R. Mejía-Domínguez, Beatriz Alcalá-Carmona, José L. Maravillas-Montero, José Carlos Páez-Franco, Ana Sofía Vargas-Castro, Jaquelin Lira-Luna, Emmanuel A. Camacho-Morán, Guillermo Juarez-Vega, David Meza-Sánchez, Carlos Núñez-Álvarez, Marina Rull-Gabayet, and Diana Gómez-Martín
- Subjects
persistent PACS ,B cells ,monocytes ,neutrophils ,chemokines ,metabolomics ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
The coronavirus disease 2019 (COVID-19) survivors are frequently observed to present persistent symptoms constituting what has been called “post-acute COVID-19 syndrome” (PACS) or “long COVID-19”. Some clinical risk factors have been identified to be associated with PACS development; however, specific mechanisms responsible for PACS pathology remain unknown. This study investigates clinical, immunological, and metabolomic risk factors associated with post-acute COVID-19 syndrome (PACS) in 51 patients, assessed 7–19 months after acute infection. Among the participants, 62.7% were male and 37.2% were female, with an average age of 47.8 years. At the follow-up, 37.2% met the criteria for PACS, revealing significant differences in immunological and metabolomic profiles at the time of acute infection. Patients with PACS were characterized by elevated levels of mature low-density granulocytes (LDGs), interleukin-8 (IL-8), pyruvate, pseudouridine, and cystine. Baseline multivariate analysis showed increased pyruvate and decreased alpha tocopherol levels. At follow-up, there was a decrease in absolute B lymphocytes and an increase in non-classical monocytes and 3-hydroxyisovaleric acid levels. These findings suggest that specific immunological and metabolomic markers during acute infection can help identify patients at higher risk of developing persistent PACS.
- Published
- 2024
- Full Text
- View/download PDF